Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 189

1.

C3 glomerulopathy - understanding a rare complement-driven renal disease.

Smith RJH, Appel GB, Blom AM, Cook HT, D'Agati VD, Fakhouri F, Fremeaux-Bacchi V, Józsi M, Kavanagh D, Lambris JD, Noris M, Pickering MC, Remuzzi G, de Córdoba SR, Sethi S, Van der Vlag J, Zipfel PF, Nester CM.

Nat Rev Nephrol. 2019 Mar;15(3):129-143. doi: 10.1038/s41581-018-0107-2. Review.

PMID:
30692664
2.

Diagnostic Utility of Exome Sequencing for Kidney Disease.

Groopman EE, Marasa M, Cameron-Christie S, Petrovski S, Aggarwal VS, Milo-Rasouly H, Li Y, Zhang J, Nestor J, Krithivasan P, Lam WY, Mitrotti A, Piva S, Kil BH, Chatterjee D, Reingold R, Bradbury D, DiVecchia M, Snyder H, Mu X, Mehl K, Balderes O, Fasel DA, Weng C, Radhakrishnan J, Canetta P, Appel GB, Bomback AS, Ahn W, Uy NS, Alam S, Cohen DJ, Crew RJ, Dube GK, Rao MK, Kamalakaran S, Copeland B, Ren Z, Bridgers J, Malone CD, Mebane CM, Dagaonkar N, Fellström BC, Haefliger C, Mohan S, Sanna-Cherchi S, Kiryluk K, Fleckner J, March R, Platt A, Goldstein DB, Gharavi AG.

N Engl J Med. 2019 Jan 10;380(2):142-151. doi: 10.1056/NEJMoa1806891. Epub 2018 Dec 26.

PMID:
30586318
3.

Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study.

Selewski DT, Ambruzs JM, Appel GB, Bomback AS, Matar RB, Cai Y, Cattran DC, Chishti AS, D'Agati VD, D'Alessandri-Silva CJ, Gbadegesin RA, Hogan JJ, Iragorri S, Jennette JC, Julian BA, Khalid M, Lafayette RA, Liapis H, Lugani F, Mansfield SA, Mason S, Nachman PH, Nast CC, Nester CM, Noone DG, Novak J, O'Shaughnessy MM, Reich HN, Rheault MN, Rizk DV, Saha MK, Sanghani NS, Sperati CJ, Sreedharan R, Srivastava T, Swiatecka-Urban A, Twombley K, Vasylyeva TL, Weaver DJ, Yin H, Zee J, Falk RJ, Gharavi AG, Gillespie BW, Gipson DS, Greenbaum LA, Holzman LB, Kretzler M, Robinson BM, Smoyer WE, Flessner M, Guay-Woodford LM, Kiryluk K; CureGN Consortium.

Kidney Int Rep. 2018 Aug 3;3(6):1373-1384. doi: 10.1016/j.ekir.2018.07.021. eCollection 2018 Nov.

4.

Kidney Transplantation in C3 Glomerulopathy: A Case Series.

Regunathan-Shenk R, Avasare RS, Ahn W, Canetta PA, Cohen DJ, Appel GB, Bomback AS.

Am J Kidney Dis. 2018 Nov 7. pii: S0272-6386(18)30978-8. doi: 10.1053/j.ajkd.2018.09.002. [Epub ahead of print]

PMID:
30413277
5.

Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.

Chertow GM, Appel GB, Block GA, Chin MP, Coyne DW, Goldsberry A, Kalantar-Zadeh K, Meyer CJ, Molitch ME, Pergola PE, Raskin P, Silva AL, Spinowitz B, Sprague SM, Rossing P.

J Diabetes Complications. 2018 Dec;32(12):1113-1117. doi: 10.1016/j.jdiacomp.2018.09.005. Epub 2018 Sep 13.

6.

C3 Glomerulopathy: A New Disease Comes of Age.

Appel GB.

Mayo Clin Proc. 2018 Aug;93(8):968-969. doi: 10.1016/j.mayocp.2018.06.014. No abstract available.

PMID:
30077212
7.

UBD modifies APOL1-induced kidney disease risk.

Zhang JY, Wang M, Tian L, Genovese G, Yan P, Wilson JG, Thadhani R, Mottl AK, Appel GB, Bick AG, Sampson MG, Alper SL, Friedman DJ, Pollak MR.

Proc Natl Acad Sci U S A. 2018 Mar 27;115(13):3446-3451. doi: 10.1073/pnas.1716113115. Epub 2018 Mar 12.

8.

Treatment of Rapidly Progressive Glomerulonephritis in the Elderly.

Appel GB, Lau WL.

Blood Purif. 2018;45(1-3):208-212. doi: 10.1159/000485367. Epub 2018 Jan 26.

9.

Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy: A Case Series.

Avasare RS, Canetta PA, Bomback AS, Marasa M, Caliskan Y, Ozluk Y, Li Y, Gharavi AG, Appel GB.

Clin J Am Soc Nephrol. 2018 Mar 7;13(3):406-413. doi: 10.2215/CJN.09080817. Epub 2018 Jan 11.

PMID:
29326307
10.

C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.

Bomback AS, Santoriello D, Avasare RS, Regunathan-Shenk R, Canetta PA, Ahn W, Radhakrishnan J, Marasa M, Rosenstiel PE, Herlitz LC, Markowitz GS, D'Agati VD, Appel GB.

Kidney Int. 2018 Apr;93(4):977-985. doi: 10.1016/j.kint.2017.10.022. Epub 2018 Jan 6.

PMID:
29310824
11.

Whole-Exome Sequencing in Adults With Chronic Kidney Disease: A Pilot Study.

Lata S, Marasa M, Li Y, Fasel DA, Groopman E, Jobanputra V, Rasouly H, Mitrotti A, Westland R, Verbitsky M, Nestor J, Slater LM, D'Agati V, Zaniew M, Materna-Kiryluk A, Lugani F, Caridi G, Rampoldi L, Mattoo A, Newton CA, Rao MK, Radhakrishnan J, Ahn W, Canetta PA, Bomback AS, Appel GB, Antignac C, Markowitz GS, Garcia CK, Kiryluk K, Sanna-Cherchi S, Gharavi AG.

Ann Intern Med. 2018 Jan 16;168(2):100-109. doi: 10.7326/M17-1319. Epub 2017 Dec 5. Erratum in: Ann Intern Med. 2018 Feb 20;168(4):308.

12.

Interstitial fibrosis scored on whole-slide digital imaging of kidney biopsies is a predictor of outcome in proteinuric glomerulopathies.

Mariani LH, Martini S, Barisoni L, Canetta PA, Troost JP, Hodgin JB, Palmer M, Rosenberg AZ, Lemley KV, Chien HP, Zee J, Smith A, Appel GB, Trachtman H, Hewitt SM, Kretzler M, Bagnasco SM.

Nephrol Dial Transplant. 2018 Feb 1;33(2):310-318. doi: 10.1093/ndt/gfw443.

13.

A proposal for standardized grading of chronic changes in native kidney biopsy specimens.

Sethi S, D'Agati VD, Nast CC, Fogo AB, De Vriese AS, Markowitz GS, Glassock RJ, Fervenza FC, Seshan SV, Rule A, Racusen LC, Radhakrishnan J, Winearls CG, Appel GB, Bajema IM, Chang A, Colvin RB, Cook HT, Hariharan S, Herrera Hernandez LP, Kambham N, Mengel M, Nath KA, Rennke HG, Ronco P, Rovin BH, Haas M.

Kidney Int. 2017 Apr;91(4):787-789. doi: 10.1016/j.kint.2017.01.002.

PMID:
28314581
14.

Thrombotic microangiopathies: Similar presentations, different therapies.

Appel GB.

Cleve Clin J Med. 2017 Feb;84(2):114-130. doi: 10.3949/ccjm.84gr.17001. Review.

15.

Predicting Post-Transplant Recurrence of IgA Nephropathy: The Importance of Crescents.

Avasare RS, Rosenstiel PE, Zaky ZS, Tsapepas DS, Appel GB, Markowitz GS, Bomback AS, Canetta PA.

Am J Nephrol. 2017;45(2):99-106. doi: 10.1159/000453081. Epub 2017 Jan 6.

16.

A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction.

Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, Sethi S, Tumlin JA, Mehta K, Hogan M, Erickson S, Julian BA, Leung N, Enders FT, Brown R, Knoppova B, Hall S, Fervenza FC.

J Am Soc Nephrol. 2017 Apr;28(4):1306-1313. doi: 10.1681/ASN.2016060640. Epub 2016 Nov 7.

17.

The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases.

Hogan MC, Reich HN, Nelson PJ, Adler SG, Cattran DC, Appel GB, Gipson DS, Kretzler M, Troost JP, Lieske JC.

Kidney Int. 2016 Nov;90(5):1080-1089. doi: 10.1016/j.kint.2016.06.020. Epub 2016 Aug 12.

18.

Complement-Mediated Glomerular Diseases: A Tale of 3 Pathways.

Bomback AS, Markowitz GS, Appel GB.

Kidney Int Rep. 2016 Jul 1;1(3):148-155. doi: 10.1016/j.ekir.2016.06.005. eCollection 2016 Sep. Review.

19.

Filgrastim-Induced Crescentic Transformation of Recurrent IgG2λ GN.

Batal I, Markowitz GS, Wong W, Avasare R, Mapara MY, Appel GB, D'Agati VD.

J Am Soc Nephrol. 2016 Jul;27(7):1911-5. doi: 10.1681/ASN.2016010061. Epub 2016 May 4.

20.

Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis.

Inker LA, Mondal H, Greene T, Masaschi T, Locatelli F, Schena FP, Katafuchi R, Appel GB, Maes BD, Li PK, Praga M, Del Vecchio L, Andrulli S, Manno C, Gutierrez E, Mercer A, Carroll KJ, Schmid CH, Levey AS.

Am J Kidney Dis. 2016 Sep;68(3):392-401. doi: 10.1053/j.ajkd.2016.02.042. Epub 2016 Mar 29.

PMID:
27032886
21.

Complete Remission in the Nephrotic Syndrome Study Network.

Gipson DS, Troost JP, Lafayette RA, Hladunewich MA, Trachtman H, Gadegbeku CA, Sedor JR, Holzman LB, Moxey-Mims MM, Perumal K, Kaskel FJ, Nelson PJ, Tuttle KR, Bagnasco SM, Hogan MC, Dell KM, Appel GB, Lieske JC, Ilori TO, Sethna CB, Fervenza FC, Hogan SL, Nachman PH, Rosenberg AZ, Greenbaum LA, Meyers KE, Hewitt SM, Choi MJ, Kopp JB, Zhdanova O, Hodgin JB, Johnstone DB, Adler SG, Avila-Casado C, Neu AM, Hingorani SR, Lemley KV, Nast CC, Brady TM, Barisoni-Thomas L, Fornoni A, Jennette JC, Cattran DC, Palmer MB, Gibson KL, Reich HN, Mokrzycki MH, Sambandam KK, Zilleruelo GE, Licht C, Sampson MG, Song P, Mariani LH, Kretzler M.

Clin J Am Soc Nephrol. 2016 Jan 7;11(1):81-9. doi: 10.2215/CJN.02560315. Epub 2015 Dec 10.

22.

Therapy: New data do not support use of abatacept in diabetic nephropathy.

Appel GB.

Nat Rev Nephrol. 2015 Dec;11(12):692-4. doi: 10.1038/nrneph.2015.178. Epub 2015 Nov 16. No abstract available.

PMID:
26568189
23.

Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN.

Sethi S, Haas M, Markowitz GS, D'Agati VD, Rennke HG, Jennette JC, Bajema IM, Alpers CE, Chang A, Cornell LD, Cosio FG, Fogo AB, Glassock RJ, Hariharan S, Kambham N, Lager DJ, Leung N, Mengel M, Nath KA, Roberts IS, Rovin BH, Seshan SV, Smith RJ, Walker PD, Winearls CG, Appel GB, Alexander MP, Cattran DC, Casado CA, Cook HT, De Vriese AS, Radhakrishnan J, Racusen LC, Ronco P, Fervenza FC.

J Am Soc Nephrol. 2016 May;27(5):1278-87. doi: 10.1681/ASN.2015060612. Epub 2015 Nov 13.

24.

New developments in the genetics, pathogenesis, and therapy of IgA nephropathy.

Magistroni R, D'Agati VD, Appel GB, Kiryluk K.

Kidney Int. 2015 Nov;88(5):974-89. doi: 10.1038/ki.2015.252. Epub 2015 Sep 16. Review.

25.

Predictors of outcome for severe IgA Nephropathy in a multi-ethnic U.S. cohort.

Arroyo AH, Bomback AS, Butler B, Radhakrishnan J, Herlitz L, Stokes MB, D'Agati V, Markowitz GS, Appel GB, Canetta PA.

Clin Nephrol. 2015 Sep;84(3):145-55. doi: 10.5414/CN108556.

PMID:
26226949
26.

A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).

Fervenza FC, Canetta PA, Barbour SJ, Lafayette RA, Rovin BH, Aslam N, Hladunewich MA, Irazabal MV, Sethi S, Gipson DS, Reich HN, Brenchley P, Kretzler M, Radhakrishnan J, Hebert LA, Gipson PE, Thomas LF, McCarthy ET, Appel GB, Jefferson JA, Eirin A, Lieske JC, Hogan MC, Greene EL, Dillon JJ, Leung N, Sedor JR, Rizk DV, Blumenthal SS, Lasic LB, Juncos LA, Green DF, Simon J, Sussman AN, Philibert D, Cattran DC; Mentor Consortium group.

Nephron. 2015;130(3):159-68. doi: 10.1159/000430849. Epub 2015 Jun 12.

PMID:
26087670
27.

Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab.

Geetha D, Kallenberg C, Stone JH, Salama AD, Appel GB, Duna G, Brunetta P, Jayne D.

J Nephrol. 2015 Feb;28(1):17-27. doi: 10.1007/s40620-014-0135-3. Epub 2014 Sep 4. Review.

28.

Rituximab treatment for fibrillary glomerulonephritis.

Hogan J, Restivo M, Canetta PA, Herlitz LC, Radhakrishnan J, Appel GB, Bomback AS.

Nephrol Dial Transplant. 2014 Oct;29(10):1925-31. doi: 10.1093/ndt/gfu189. Epub 2014 May 27.

PMID:
24867652
29.

Use of bortezomib in heavy-chain deposition disease: a report of 3 cases.

Patel K, Dillon JJ, Leung N, Bomback AS, Appel GB, D'Agati V, Canetta PA.

Am J Kidney Dis. 2014 Jul;64(1):123-7. doi: 10.1053/j.ajkd.2014.01.425. Epub 2014 Mar 5.

PMID:
24613055
30.

Diagnostic tests and treatment options in glomerular disease: 2014 update.

Hogan J, Mohan P, Appel GB.

Am J Kidney Dis. 2014 Apr;63(4):656-66. doi: 10.1053/j.ajkd.2013.09.019. Epub 2013 Nov 14. Review.

PMID:
24239051
31.

C3 glomerulopathy: consensus report.

Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Frémeaux-Bacchi V, Gale DP, Goicoechea de Jorge E, Griffin G, Harris CL, Holers VM, Johnson S, Lavin PJ, Medjeral-Thomas N, Paul Morgan B, Nast CC, Noel LH, Peters DK, Rodríguez de Córdoba S, Servais A, Sethi S, Song WC, Tamburini P, Thurman JM, Zavros M, Cook HT.

Kidney Int. 2013 Dec;84(6):1079-89. doi: 10.1038/ki.2013.377. Epub 2013 Oct 30.

32.

Glomerular diseases: emerging tests and therapies for IgA nephropathy.

Canetta PA, Kiryluk K, Appel GB.

Clin J Am Soc Nephrol. 2014 Mar;9(3):617-25. doi: 10.2215/CJN.07260713. Epub 2013 Sep 26. Review.

33.

Toward a working definition of C3 glomerulopathy by immunofluorescence.

Hou J, Markowitz GS, Bomback AS, Appel GB, Herlitz LC, Barry Stokes M, D'Agati VD.

Kidney Int. 2014 Feb;85(2):450-6. doi: 10.1038/ki.2013.340. Epub 2013 Sep 25.

34.

Treatment of idiopathic FSGS with adrenocorticotropic hormone gel.

Hogan J, Bomback AS, Mehta K, Canetta PA, Rao MK, Appel GB, Radhakrishnan J, Lafayette RA.

Clin J Am Soc Nephrol. 2013 Dec;8(12):2072-81. doi: 10.2215/CJN.02840313. Epub 2013 Sep 5.

35.

Glomerular disease: ANCA-associated GN--to PLEX or not to PLEX?

Bomback AS, Appel GB.

Nat Rev Nephrol. 2013 Aug;9(8):436-8. doi: 10.1038/nrneph.2013.126. Epub 2013 Jun 25. No abstract available.

PMID:
23797203
36.

Membranoprolferative glomerulonephritis - mechanisms and treatment.

Appel GB.

Contrib Nephrol. 2013;181:163-74. doi: 10.1159/000348635. Epub 2013 May 8. Review.

PMID:
23689578
37.

New diagnostic tests and new therapies for glomerular diseases.

Appel GB, Appel AS.

Blood Purif. 2013;35(1-3):81-5. doi: 10.1159/000345185. Epub 2013 Jan 22. Review.

38.

Update on the treatment of lupus nephritis.

Hogan J, Appel GB.

Curr Opin Nephrol Hypertens. 2013 Mar;22(2):224-30. doi: 10.1097/MNH.0b013e32835d921c. Review.

PMID:
23328501
39.

Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach.

Gadegbeku CA, Gipson DS, Holzman LB, Ojo AO, Song PX, Barisoni L, Sampson MG, Kopp JB, Lemley KV, Nelson PJ, Lienczewski CC, Adler SG, Appel GB, Cattran DC, Choi MJ, Contreras G, Dell KM, Fervenza FC, Gibson KL, Greenbaum LA, Hernandez JD, Hewitt SM, Hingorani SR, Hladunewich M, Hogan MC, Hogan SL, Kaskel FJ, Lieske JC, Meyers KE, Nachman PH, Nast CC, Neu AM, Reich HN, Sedor JR, Sethna CB, Trachtman H, Tuttle KR, Zhdanova O, Zilleruelo GE, Kretzler M.

Kidney Int. 2013 Apr;83(4):749-56. doi: 10.1038/ki.2012.428. Epub 2013 Jan 16.

40.

Impact of the ALMS and MAINTAIN trials on the management of lupus nephritis.

Morris HK, Canetta PA, Appel GB.

Nephrol Dial Transplant. 2013 Jun;28(6):1371-6. doi: 10.1093/ndt/gfs447. Epub 2012 Dec 11. Review.

PMID:
23233523
41.

Aldosterone blockade as an alternative renin-angiotensin-aldosterone system blocking agent in cases of treatment associated anemia.

Avasare RS, Appel GB, Bomback AS.

Clin Nephrol. 2014 May;81(5):350-4. doi: 10.5414/CN107677.

PMID:
23211336
42.

Diagnosis and treatment of lupus nephritis flares--an update.

Sprangers B, Monahan M, Appel GB.

Nat Rev Nephrol. 2012 Dec;8(12):709-17. doi: 10.1038/nrneph.2012.220. Epub 2012 Nov 13. Review.

PMID:
23147758
43.

Pathogenesis of the C3 glomerulopathies and reclassification of MPGN.

Bomback AS, Appel GB.

Nat Rev Nephrol. 2012 Nov;8(11):634-42. doi: 10.1038/nrneph.2012.213. Epub 2012 Oct 2. Review.

PMID:
23026947
44.

Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.

Bomback AS, Rekhtman Y, Klemmer PJ, Canetta PA, Radhakrishnan J, Appel GB.

J Am Soc Hypertens. 2012 Sep-Oct;6(5):338-45. doi: 10.1016/j.jash.2012.07.003.

PMID:
22995802
45.

Lupus nephritis: Implications of the new ACR lupus nephritis guidelines.

Anders HJ, Appel GB.

Nat Rev Nephrol. 2012 Sep;8(9):500-1. doi: 10.1038/nrneph.2012.162. Epub 2012 Jul 24.

PMID:
22825673
46.

Rituximab in membranous nephropathy: is it a first-line treatment?

Appel GB.

J Am Soc Nephrol. 2012 Aug;23(8):1280-2. doi: 10.1681/ASN.2012060602. Epub 2012 Jul 12. No abstract available.

47.

Idiopathic membranous nephropathy: clinical and histologic prognostic features and treatment patterns over time at a tertiary referral center.

Sprangers B, Bomback AS, Cohen SD, Radhakrishnan J, Valeri A, Markowitz GS, D'Agati V, Appel GB.

Am J Nephrol. 2012;36(1):78-89. doi: 10.1159/000339628. Epub 2012 Jun 27.

PMID:
22739228
48.

Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial.

Bomback AS, Canetta PA, Beck LH Jr, Ayalon R, Radhakrishnan J, Appel GB.

Am J Nephrol. 2012;36(1):58-67. doi: 10.1159/000339287. Epub 2012 Jun 19.

PMID:
22722778
49.

Pathology after eculizumab in dense deposit disease and C3 GN.

Herlitz LC, Bomback AS, Markowitz GS, Stokes MB, Smith RN, Colvin RB, Appel GB, D'Agati VD.

J Am Soc Nephrol. 2012 Jul;23(7):1229-37. doi: 10.1681/ASN.2011121186. Epub 2012 Jun 7.

50.

Eculizumab for dense deposit disease and C3 glomerulonephritis.

Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, Stokes MB, Markowitz GS, D'Agati VD, Canetta PA, Radhakrishnan J, Appel GB.

Clin J Am Soc Nephrol. 2012 May;7(5):748-56. doi: 10.2215/CJN.12901211. Epub 2012 Mar 8.

Supplemental Content

Loading ...
Support Center